APGE Quote, Financials, Valuation and Earnings

Galecto, Inc. has a net margin of -- compared to Apogee Therapeutics, Inc.'s net margin of --. Apogee Therapeutics, Inc.'s return on equity of -38.09% beat Galecto, Inc.'s return on equity of -123.72%.

Apogee Therapeutics, Inc. has a consensus price target of $103.50, signalling upside risk potential of 29.6%. On the other hand Galecto, Inc. has an analysts' consensus of $41.00 which suggests that it could grow by 38.61%. Given that Galecto, Inc. has higher upside potential than Apogee Therapeutics, Inc., analysts believe Galecto, Inc. is more attractive than Apogee Therapeutics, Inc..

Apogee Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Galecto, Inc. has a beta of 1.417, suggesting its more volatile than the S&P 500 by 41.723%.

Apogee Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Galecto, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apogee Therapeutics, Inc. pays -- of its earnings as a dividend. Galecto, Inc. pays out -- of its earnings as a dividend.

Apogee Therapeutics, Inc. quarterly revenues are --, which are smaller than Galecto, Inc. quarterly revenues of --. Apogee Therapeutics, Inc.'s net income of -$65M is lower than Galecto, Inc.'s net income of -$3.1M. Notably, Apogee Therapeutics, Inc.'s price-to-earnings ratio is -- while Galecto, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apogee Therapeutics, Inc. is -- versus -- for Galecto, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Structure Therapeutics, Inc. has a net margin of -- compared to Apogee Therapeutics, Inc.'s net margin of --. Apogee Therapeutics, Inc.'s return on equity of -38.09% beat Structure Therapeutics, Inc.'s return on equity of -25.55%.

Apogee Therapeutics, Inc. has a consensus price target of $103.50, signalling upside risk potential of 29.6%. On the other hand Structure Therapeutics, Inc. has an analysts' consensus of $107.80 which suggests that it could grow by 17.34%. Given that Apogee Therapeutics, Inc. has higher upside potential than Structure Therapeutics, Inc., analysts believe Apogee Therapeutics, Inc. is more attractive than Structure Therapeutics, Inc..

Apogee Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Structure Therapeutics, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Apogee Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Structure Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apogee Therapeutics, Inc. pays -- of its earnings as a dividend. Structure Therapeutics, Inc. pays out -- of its earnings as a dividend.

Apogee Therapeutics, Inc. quarterly revenues are --, which are smaller than Structure Therapeutics, Inc. quarterly revenues of --. Apogee Therapeutics, Inc.'s net income of -$65M is higher than Structure Therapeutics, Inc.'s net income of -$65.8M. Notably, Apogee Therapeutics, Inc.'s price-to-earnings ratio is -- while Structure Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apogee Therapeutics, Inc. is -- versus -- for Structure Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Nektar Therapeutics has a net margin of -- compared to Apogee Therapeutics, Inc.'s net margin of -301.29%. Apogee Therapeutics, Inc.'s return on equity of -38.09% beat Nektar Therapeutics's return on equity of -327.67%.

Apogee Therapeutics, Inc. has a consensus price target of $103.50, signalling upside risk potential of 29.6%. On the other hand Nektar Therapeutics has an analysts' consensus of $114.43 which suggests that it could grow by 213.25%. Given that Nektar Therapeutics has higher upside potential than Apogee Therapeutics, Inc., analysts believe Nektar Therapeutics is more attractive than Apogee Therapeutics, Inc..

Apogee Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Nektar Therapeutics has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.624%.

Apogee Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Nektar Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apogee Therapeutics, Inc. pays -- of its earnings as a dividend. Nektar Therapeutics pays out -- of its earnings as a dividend.

Apogee Therapeutics, Inc. quarterly revenues are --, which are smaller than Nektar Therapeutics quarterly revenues of $11.8M. Apogee Therapeutics, Inc.'s net income of -$65M is lower than Nektar Therapeutics's net income of -$35.5M. Notably, Apogee Therapeutics, Inc.'s price-to-earnings ratio is -- while Nektar Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apogee Therapeutics, Inc. is -- versus 37.67x for Nektar Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to Apogee Therapeutics, Inc.'s net margin of 38.89%. Apogee Therapeutics, Inc.'s return on equity of -38.09% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Apogee Therapeutics, Inc. has a consensus price target of $103.50, signalling upside risk potential of 29.6%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $830.04 which suggests that it could grow by 9.87%. Given that Apogee Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Apogee Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Apogee Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Apogee Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.47% to investors and pays a quarterly dividend of $0.88 per share. Apogee Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Apogee Therapeutics, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Apogee Therapeutics, Inc.'s net income of -$65M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Apogee Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apogee Therapeutics, Inc. is -- versus 5.84x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.